// App-Quantinova.ai

: D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely Ill medical patients: insights from the APEX trial

Researchers

Presenter

  • R.D. Hull

Principal Investigators

  • A. Gold

  • A.T. Cohen

Medical Centers

  • University of Calgary, Gastroenterology, Calgary, Canada

  • Portola Pharmaceuticals, Inc., South San Francisco, United States

  • Guy's Hospital, Department of Haematological Medicine, London, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • D-dimer

Drug/Treatment

  • betrixaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Portola Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved